GlassScriptPhysician profile
Denise Balacich
NPI 1619319266
$2,162.09
in general payments reported to CMS, 2019-2025
12 companies · $705 in 2025
The $705 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $14.21 · 2021: $14.17 · 2022: $212 · 2023: $524 · 2024: $384 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $454.98 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $378.30 | 2023-2025 | Miebo, Xiidra |
| Alcon Vision LLC | $356.57 | 2022-2025 | Rocklatan, Tryptyr, Rhopressa |
| Biotissue Holdings INC. | $252.55 | 2025 | |
| Oyster Point Pharma, INC. | $156.68 | 2023-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $138.91 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $125.00 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $118.33 | 2019-2023 | Cequa |
| Coopervision INC. | $107.55 | 2022 | |
| Kala Pharmaceuticals, INC. | $33.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $26.94 | 2019-2021 | |
| Abbvie INC. | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Balacich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.